Cytokines in the systemic inflammatory response syndrome: a review

Introduction Patients subject to major surgery, suffering sepsis, major trauma, or following cardiopulmonary bypass exhibit a systemic inflammatory response. This inflammatory response involves a complex array of inflammatory polypeptide molecules known as cytokines. It is well accepted that the loss of local control of the release of these cytokines leads to systemic inflammation and potentially deleterious consequences including the Systemic Inflammatory Response Syndrome, Multi-Organ Dysfunction Syndrome, shock and death. Methods The Medline database was searched for literature on mechanisms involved in the development of SIRS and potential targets for modifying the inflammatory response. We focus on the novel therapy of cytokine adsorption as a promising removal technology. Results Accumulating data from human studies and experimental animal models suggests that both pro- and anti- inflammatory cytokines are released following a variety of initiating stimuli including endotoxin release, complement activation, ischaemia reperfusion injury and others. Discussion Pro-and anti-inflammatory cytokines interact in a complex and unpredictable manner to influence the immune system and eventually cause multiple end organ effects. Cytokine adsorption therapy provides a potential solution to improving outcomes following Systemic Inflammatory Response Syndrome.

[1]  M. Kretzschmar,et al.  Plasma levels of glutathione, alpha-tocopherol and lipid peroxides in polytraumatized patients; evidence for a stimulating effect of TNF alpha on glutathione synthesis. , 1998, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[2]  John P. Johnson,et al.  Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. , 1998, Critical care medicine.

[3]  K. Lachapelle,et al.  High-dose insulin therapy attenuates systemic inflammatory response in coronary artery bypass grafting patients. , 2008, The Annals of thoracic surgery.

[4]  M. Kretzschmar,et al.  Plasma levels of glutathione, α-tocopherol and lipid peroxides in polytraumatized patients; evidence for a stimulating effect of TNF α on glutathione synthesis , 1998 .

[5]  L. Socha,et al.  Elevation in interleukin 13 levels in patients diagnosed with systemic inflammatory response syndrome , 2006, Intensive Care Medicine.

[6]  I. C. Tudor,et al.  The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.

[7]  R. Bellomo,et al.  Super high flux hemofiltration: a new technique for cytokine removal , 2002, Intensive Care Medicine.

[8]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[9]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[10]  Z. Xie,et al.  TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation. , 1999, The American journal of physiology.

[11]  S. Calvano,et al.  Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia , 2004, Shock.

[12]  V. Pettilä,et al.  Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation 1 , 2004, Journal of thrombosis and haemostasis : JTH.

[13]  John A Kellum,et al.  Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-&kgr;B DNA binding, and improves short-term survival in lethal endotoxemia* , 2004, Critical care medicine.

[14]  R. Landmann,et al.  Function of soluble CD14 in serum from patients with septic shock. , 1996, The Journal of infectious diseases.

[15]  J. Kremer,et al.  Interleukin-1, -6 and tumor necrosis factor-alpha release is down-regulated in whole blood from septic patients. , 1996, Acta haematologica.

[16]  S. Bucklin,et al.  Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia , 1995, Antimicrobial agents and chemotherapy.

[17]  K. Sugimura,et al.  Direct hemoperfusion by using Lixelle column for the treatment of systemic inflammatory response syndrome. , 2002, International journal of molecular medicine.

[18]  N. Shapiro,et al.  Early goal-directed therapy: a UK perspective , 2006, Emergency Medicine Journal.

[19]  H. Werner,et al.  Amrinone increases ventricular contractility and diastolic compliance in endotoxemia. , 1995, American journal of respiratory and critical care medicine.

[20]  Ning Li,et al.  Effect of glutamine on change in early postoperative intestinal permeability and its relation to systemic inflammatory response. , 2004, World journal of gastroenterology.

[21]  M. Antonelli,et al.  Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. , 2009, JAMA.

[22]  R. Bone,et al.  Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS) , 1996, Annals of Internal Medicine.

[23]  J. Platt,et al.  The etiology of sepsis: turned inside out. , 2006, Trends in molecular medicine.

[24]  G. Nieman,et al.  Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. , 2005, The journal of extra-corporeal technology.

[25]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[26]  W. Feuer,et al.  Effects of Treatment with Pentoxifylline on the Cardiovascular Manifestations of Group B Streptococcal Sepsis in the Piglet1 , 1996, Pediatric Research.

[27]  C. Ronco,et al.  Continuous plasma filtration coupled with sorbents. , 1998, Kidney international. Supplement.

[28]  M. Nagaki,et al.  Removal of Endotoxin and Cytokines by Adsorbents and the Effect of Plasma Protein Binding , 1991, The International journal of artificial organs.

[29]  M. Berger,et al.  Antioxidant supplementation in sepsis and systemic inflammatory response syndrome , 2007, Critical care medicine.

[30]  J. Peters,et al.  Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNFα plasma concentrations , 1997, Intensive Care Medicine.

[31]  Steven B. Johnson,et al.  Coagulation and complement protein differences between septic and uninfected systemic inflammatory response syndrome patients. , 2007, The Journal of trauma.

[32]  J. Schopohl,et al.  Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. , 1999, Critical care medicine.

[33]  I. Young,et al.  The effect of lower limb ischaemia-reperfusion on intestinal permeability and the systemic inflammatory response. , 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[34]  D. Kufe,et al.  Clinical studies with tumour necrosis factor. , 2007, Ciba Foundation symposium.

[35]  A. Lloyd,et al.  The in vitro adsorption of cytokines by polymer-pyrolysed carbon. , 2006, Biomaterials.

[36]  P. Barie,et al.  International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. , 2007, Surgery.

[37]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[38]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[39]  Gerhard Rakhorst,et al.  Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. , 2005, Chest.

[40]  M. D. Magdi M.I. Yassin,et al.  Lower Limb Ischemia-Reperfusion Injury Triggers a Systemic Inflammatory Response and Multiple Organ Dysfunction , 2001, World Journal of Surgery.

[41]  K. Eckardt,et al.  Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock* , 2005, Critical care medicine.

[42]  S. Ash,et al.  Treatment of systemic inflammatory response syndrome by push-pull powdered sorbent pheresis: a Phase 1 clinical trial. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[43]  S. Mikhalovsky Emerging technologies in extracorporeal treatment: focus on adsorption , 2003, Perfusion.

[44]  S. Ash,et al.  Cytokines and endotoxin removal by sorbents and its application in push-pull sorbent-based pheresis: the BioLogic-DTPF System. , 1999, Artificial organs.

[45]  F. Santolaria,et al.  Prognostic value of cytokines in SIRS general medical patients. , 2001, Cytokine.

[46]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[47]  S. Hoerstrup,et al.  Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass. , 2001, The Annals of thoracic surgery.

[48]  J. Christman,et al.  Nuclear factor k B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy , 1998, Intensive Care Medicine.

[49]  P. Thompson,et al.  Modulatory effects of sCD14 and LBP on LPS-host cell interactions , 2005, Journal of endotoxin research.

[50]  Rinaldo Bellomo,et al.  The effect of coupled haemofiltration and adsorption on inflammatory cytokines in an ex vivo model. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  H. Hirasawa,et al.  Cytokine Adsorptive Property of Various Adsorbents in Immunoadsorption Columns and a Newly Developed Adsorbent: An in vitro Study , 2004, Blood Purification.

[52]  Incidence of Gram‐negative bacteraemia in sepsis syndrome Implications for immunotherapy , 1994, Anaesthesia.

[53]  J. Brock‐Utne Incidence of Gram‐negative bacteraemia in sepsis syndrome , 1995, Anaesthesia.

[54]  M. Zembala,et al.  Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis , 1996, European Journal of Pediatrics.

[55]  M. Langer,et al.  The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock , 1995, Intensive Care Medicine.

[56]  E. N. Wardle Bacterial translocation in multiple organ failure: cause or epiphenomenon still unproven. , 1998, The British journal of surgery.

[57]  F. Farrokhyar,et al.  Pulse low dose steroids attenuate post-cardiopulmonary bypass SIRS; SIRS I. , 2006, The Journal of surgical research.

[58]  Joel D. Graham,et al.  Reducing the Effects of the Systemic Inflammatory Response to Cardiopulmonary Bypass: Can Single Dose Steroids Blunt Systemic Inflammatory Response Syndrome? , 2008, ASAIO journal.

[59]  K. Reinhart,et al.  Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned , 2001, Critical care medicine.

[60]  J. Blache,et al.  Early postoperative compensatory anti‐inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer , 2002, The British journal of surgery.

[61]  N. MacIntyre,et al.  A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.

[62]  J. Vincent,et al.  Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. , 1991, Cytokine.